Opportunity for investors with substantial losses to pursue Ocugen, Inc. class action – OCGN

0

SAN DIEGO – (COMMERCIAL THREAD) –Robbins Geller Rudman & Dowd LLP announces that purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021 inclusive (the “Class Period”) have until August 17, 2021 to solicit appointment as applicant Ocugen class action lawsuit. The case is captioned Nicanor v. Ocugen, Inc., No. 21-cv-02725, and is attributed to C. Darnell Jones, II of the Eastern District of Pennsylvania. the Ocugen The class action accuses Ocugen and some of its executives of violations of the Securities Exchange Act of 1934.

If you wish to serve as the principal applicant of the Ocugen class action or have questions about your rights regarding the Ocugen class action, please provide your information here or contact lawyer JC Sanchez de Robbins Geller, at 800 / 449-4900 or 619 / 231-1058 or by email at [email protected] The principal applicant’s requests for the Ocugen The class action must be filed with the court no later than August 17, 2021.

CASE ALLEGATIONS: the Ocugen The Class Action alleges that, throughout the Class Period, the Defendants made false and misleading statements and failed to disclose that: (i) the information Ocugen submitted to the Food and Drug Administration of the United States (“FDA”) were insufficient to justify an Emergency Use Authorization (“EUA”); (ii) Ocugen would not file an EUA with the FDA; and (iii) as a result, Ocugen’s financial statements, as well as the statements of the defendants regarding Ocugen’s business, operations and prospects were false and misleading and / or lacked reasonable basis.

On June 10, 2021, Ocugen issued a press release announcing that it would pursue a Biologics License Application (“BLA”) with the FDA instead of the previously announced EUA. In doing so, Ocugen revealed that “[t]FDA provided comments to Ocugen regarding the main dossier the company had previously submitted and recommended that Ocugen pursue a BLA submission instead of an EUA application for its vaccine candidate and requested additional information and data . Ocugen is in talks with the FDA to understand the additional information required to support a BLA submission. The Company anticipates that data from an additional clinical trial will be required to support the submission. At this news, Ocugen’s share price fell more than 28%, hurting investors.

THE MAIN COMPLAINANT PROCESS: The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ocugen securities during the Recourse Period to seek appointment as principal plaintiff in the Ocugen class action lawsuit. A principal plaintiff is generally the plaintiff with the greatest financial interest in the remedy sought by the putative class which is also typical and adequate of the putative class. A principal applicant acts on behalf of all other class members by ordering Ocugen class action lawsuit. The lead plaintiff can choose a law firm of their choice to litigate the Ocugen class action lawsuit. The ability of an investor to participate in any potential future recovery of the Ocugen the class action does not depend on the function of principal plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 offices across the country, Robbins Geller Rudman & Dowd LLP is the largest US law firm representing investors in securities class actions. Robbins Geller lawyers have secured many of the largest shareholder recoveries in history, including the largest securities class action recovery ever – $ 7.2 billion – in In re Enron Corp. Dry. Litigation. The 2020 ISS Securities Class Action Services Top 50 report ranked Robbins Geller # 1 for recovering $ 1.6 billion from investors last year, more than double the amount recovered by any other company from securities claimants. Please visit http://www.rgrdlaw.com for more information.

Lawyer advertising.

Past results do not guarantee future results.

Services can be performed by lawyers in one of our offices.

Leave A Reply

Your email address will not be published.